A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Condition: Human Papilloma Virus Infection Interventions: Biological: Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli); Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae) Sponsors: Beijing Health Guard Biotechnology, Inc; Jiangsu Province Centers for Disease Control and Prevention; National Institutes for Food and Drug Control, China; Nanjing Sangruisi pharmtech Ltd.; Shanghai Canming pharmtech Ltd. Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 23, 2023 Category: Research Source Type: clinical trials